News | December 04, 2024
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Indoco is comprehensively working on the remedial action plan
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Subscribe To Our Newsletter & Stay Updated
